Advanced porous plastics for medical & life science applications
A selection of BioVyon components.
BioVyon range have been incorporated into products to achieve more sensitive analysis, better healthcare, improved medical knowledge and faster diagnosis and treatment of diseases.
Porvair Sciences, original manufacturers of porous plastics, will be showcasing its advanced materials for the medical and life science markets at this year’s COMPAMED exhibition in Dusseldorf, Germany.
Visitors will be able to learn how Porvair's BioVyon range of high-performance porous materials have been incorporated into products to achieve more sensitive analysis, better healthcare, improved medical knowledge as well as faster diagnosis and treatment of diseases. Also on display, will be the latest life science and medical products and application solutions from Porvair’s fast-growing Laboratory Division.
Alan Hughes, Advanced Materials account manager at Porvair Sciences commented: "The requirements of porous materials used in devices and systems for medical diagnostics and drug delivery applications are usually far more stringent than those for industrial applications. They need to be contamination-free with very low levels of leachables and with full traceability. Regulatory approval is also an essential prerequisite for many products in these sectors." He added: "Drawing upon the wide range of production equipment in our Wrexham, UK facility, Porvair Sciences not only manufacture the BioVyon materials but can assemble finished products in our cleanroom facility for OEM partners to the high standards demanded by these regulated markets."
BioVyon range of advanced porous plastic materials are being used in applications including drug filtration and purification, catheter vents, bone cement mixing in the operating theatre and nasal spray filters.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.